Biotech News
Timberlyne Therapeutics Secures $180M Series A to Best-in-Class Anti-CD38 Monoclonal Antibody
Timberlyne Therapeutics, a clinical-stage biopharmaceutical company, has closed a $180 million Series A funding round to advance its monoclonal antibody, CM313, targeting autoimmune diseases with unmet medical needs. The round was led by Abingworth, Bain Capital Life Sciences, and Venrock
17 January 2025
Stay ahead of trends and best practices
